Table 1.
Characteristics of the Study Population, Pre-ECCO2R Ventilation and Circuit Management
| Parameters | Overall Population N = 16 |
|---|---|
| Age (years) | 62 [54–65] |
| Gender (%) Female Male |
6 (38) 10 (62) |
| BMI (kg/m2) | 28 [23–33] |
| Comorbidities (%) Chronic lung disease Hypertension CKD Immunocompromised Diabetes |
13 (81) 7 (44) 2 (13) 2 (13) 2 (13) |
| ARF etiology (%) COPD Asthma |
13 (81) 3 (19) |
| SOFA at admission | 7 [5–8] |
| APACHE II at admission | 13 [9–15] |
| Pre-ECCO2R mechanical ventilation days (days) | 0 [0–0] |
| Pre-ECCO2R noninvasive ventilation days (days) | 0 [0–1] |
| ECCO2R and anticoagulation | |
| Cannulation technique: percutaneous (%) | 16 (100) |
| Cannula size (%) 20 Fr 23 Fr |
8 (50) 8 (50) |
| Anticoagulation: UFH (%) | 16 (100) |
| UFH bolus dose at cannulation (U/kg) | 67 [56–71] |
| UFH dose (U/kg/h) | 14 [11–19] |
| aPTTratio | 1.6 [1.4–1.9] |
| ATIII (%) | 95 [81–105] |
| Blood products during ECCO2R course PRBC Fresh frozen plasma Platelets pool |
0 [0–0] 0 [0–0] 0 [0 –0] |
aPTT, activated partial thromboplastin time; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ECCO2R, extracorporeal CO2 removal; PRBC, packed red blood cells; SAPSII, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment; UFH, unfractionated heparin.